(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI-enabled discovery, personalized and rare-disease research, and chronic care. Trends favor end-to-end outsourcing, advanced screening and regional sourcing.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Outsourcing Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Drug Discovery Outsourcing Market Projected to Reach $6.15 Billion by 2030 as Pharmaceutical R&D Demand Accelerates
The global drug discovery outsourcing market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly engage external research partners to manage complex development pipelines, control research and development costs, and access specialized scientific expertise. The market is expected to grow from $4.24 billion in 2025 to $4.57 billion in 2026, representing a compound annual growth rate (CAGR) of 8%.
Historical market growth has been supported by the rising complexity of drug development programs, increasing R&D cost pressures, the expansion of biotechnology startups, and growing demand for advanced scientific capabilities. Pharmaceutical organizations are increasingly using outsourced drug discovery services to supplement internal resources, accelerate research programs, and gain access to specialized technologies and infrastructure.
The drug discovery outsourcing market is forecast to reach $6.15 billion by 2030, expanding at a CAGR of 7.7% from 2026. Growth during the forecast period is expected to be driven by the adoption of artificial intelligence-enabled drug discovery platforms, increasing research into rare and complex diseases, the expansion of personalized medicine, greater investment in outsourced innovation models, and the continued globalization of pharmaceutical R&D.
Key drug discovery outsourcing market trends include the adoption of integrated service models, rising demand for end-to-end preclinical outsourcing, increased use of advanced screening platforms, expansion of specialized contract research organization capabilities, and a stronger focus on shortening drug development timelines. These trends are encouraging service providers to broaden their scientific capabilities and deliver more coordinated support across discovery and preclinical workflows.
The increasing prevalence of chronic diseases is expected to remain a significant market growth driver. Aging populations, lifestyle-related risk factors, urbanization, and environmental influences are contributing to a greater global disease burden and increasing demand for new treatments. Drug discovery outsourcing enables pharmaceutical and biotechnology companies to access specialized expertise, advanced research technologies, and scalable development resources while reducing costs and accelerating timelines.
In April 2025, the U.S. Centers for Disease Control and Prevention reported that approximately 194 million U.S. adults, or 76.4% of the adult population, had one or more chronic conditions in 2023. Approximately 130 million adults, representing 51.4%, reported having multiple chronic conditions. This growing healthcare burden is increasing pressure on life sciences companies to advance new therapeutic candidates efficiently, supporting demand for outsourced drug discovery and development services.
Innovation in digital health technologies is also influencing the competitive direction of the drug discovery outsourcing market. In November 2023, AstraZeneca launched Evinova, a health technology business created to support life sciences innovation and improve clinical trial delivery. The business offers globally scalable digital products and services that have demonstrated effectiveness in AstraZeneca clinical trials conducted across more than 40 countries. By improving clinical trial design and execution, the initiative is intended to reduce the time and costs associated with developing new medicines.
Strategic acquisitions are further reshaping the market as service providers seek to expand their capabilities across the drug development lifecycle. In July 2024, Poland-based Selvita SA acquired PozLab for an undisclosed amount. The transaction strengthened Selvita's drug development operations and expanded its ability to provide small-molecule drug manufacturing services for early-stage clinical trials. The acquisition also supports Selvita's strategy of offering more comprehensive pharmaceutical research and development solutions.
Drug discovery outsourcing services cover chemistry and biological research, including target identification and screening, target validation, functional informatics, lead identification, candidate optimization, and preclinical development. Research programs may use in vitro, cellular, and animal models across therapeutic areas such as oncology, immunology, cardiovascular disease, central nervous system disorders, gastrointestinal conditions, hematology, respiratory disease, and infectious diseases. Demand is generated by pharmaceutical and biotechnology companies, academic institutions, and other research organizations.
North America was the largest region in the drug discovery outsourcing market in 2025, supported by established pharmaceutical and biotechnology industries, significant R&D investment, and access to advanced research infrastructure. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries analyzed include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Service Type: Chemistry Services; Biological Services
2) By Workflow: Target Identification And Screening; Target Validation And Functional Informatics; Lead Identification And Candidate Optimization; Preclinical Development; Other Workflows
3) By Disease Model: In Vitro Models; Animal Models; Cellular Models; Other Disease Models
4) By Therapeutic Area: Cardiovascular; Central Nervous System (CNS); Gastrointestinal; Hematology; Respiratory System; Infectious Disease; Oncology; Immunology; Other Therapeutic Areas
5) By End User: Pharmaceutical And Biotechnology Companies; Academic Institutes; Other End Users
Subsegments:
1) By Chemistry Services: Custom Synthesis And Manufacturing; Medicinal Chemistry; Combinatorial Chemistry; Hit Identification And Lead Optimization; Process Chemistry And Scale-Up; Analytical Chemistry Services; Chemical Library Design And Screening; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Profiling
2) By Biological Services: Cell-Based Assays And Screening; Target Identification And Validation; In Vitro And In Vivo Testing; Biomarker Discovery And Development; Toxicology Studies; Genomics And Proteomics Services; Animal Models For Preclinical Development; Biological Safety And Efficacy Testing; Biopharmaceutical Development And Manufacturing.
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment